Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Fractyl Health, Inc.. The associated price target remains the same with $8.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight the promising outlook for Fractyl Health, Inc. The recent positive results from the REVEAL-1 study demonstrated sustained weight maintenance and further weight loss in participants after discontinuing GLP-1 therapy, which underscores the potential of Fractyl’s Revita DMR procedure. These findings suggest that Revita could offer a durable solution for weight management, setting it apart as a first-in-class treatment.
Furthermore, the anticipation of favorable data from the upcoming REMAIN-1 study in 2026 strengthens confidence in the company’s future prospects. The ability of Revita to maintain weight loss where other treatments typically see a rebound is a significant advantage. This potential for long-term efficacy supports the Buy rating, as it positions Fractyl Health, Inc. to capitalize on a growing market need for effective metabolic disease treatments.
In another report released on November 20, Canaccord Genuity also maintained a Buy rating on the stock with a $8.00 price target.